KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Commitments And ObligationsCost Of SalesDevelopment ExpensesEffective Tax Rate %Employees By RegionGross Margin %Gross ProfitIncome Before Income Taxes By RegionInventory BreakdownLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX BreakdownProduct Revenue By RegionProduct Revenue By Region %Product Revenue By Region AnnualProduct Revenue By Region Annual %Property And Equipment BreakdownResearch Expenses BreakdownRevenue By Business VerticalRevenue By Business Vertical (Annual)Revenue By Business Vertical AnnualRevenue By Customer (Annual) %Revenue By Location Of Customer (Product)Revenue By Location Of Customer (Product) %Revenue By Location Of Customer (Product Annual)Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category (Annual)Revenue Mix By Business Vertical Annual %Revenue Mix By Product Category (Annual) %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gross Profit: 2009-2024

Historic Gross Profit for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to $9.5 billion.

  • Vertex Pharmaceuticals' Gross Profit rose 11.86% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 billion, marking a year-over-year increase of 10.53%. This contributed to the annual value of $9.5 billion for FY2024, which is 10.25% up from last year.
  • Vertex Pharmaceuticals' Gross Profit amounted to $9.5 billion in FY2024, which was up 10.25% from $8.6 billion recorded in FY2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Profit peaked at $9.5 billion during FY2024, and registered a low of $5.5 billion during FY2020.
  • Moreover, its 3-year median value for Gross Profit was $8.6 billion (2023), whereas its average is $8.6 billion.
  • Data for Vertex Pharmaceuticals' Gross Profit shows a peak YoY spiked of 51.30% (in 2020) over the last 5 years.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Profit (Yearly) stood at $5.5 billion in 2020, then increased by 21.95% to $6.7 billion in 2021, then grew by 17.69% to $7.9 billion in 2022, then grew by 9.64% to $8.6 billion in 2023, then climbed by 10.25% to $9.5 billion in 2024.